15 completed, 3 recruiting, 3 terminated, 2 withdrawn. 10 Phase 1, 9 Phase 2, 5 Phase 3, 1 Not applicable, 1 Phase 4.
Follow nirmatrelvir: new trials by email Literature Review of nirmatrelvir trials Research Report on nirmatrelvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants Paxlovid, Nirmatrelvir/ritonavir - Biological Availability, Healthy Participants | Phase 1 | Withdrawn | Pfizer | 2025-08-15 | 2025-12-26 | |
| Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients combination therapy, SOC - COVID-19, SARS-CoV-2 | Not applicable | Not yet recruiting | National Taiwan University Hospital | 40 | 2024-09-21 | 2024-09-25 |
| A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID. Nirmatrelvir, Ritonavir, Placebo - Long COVID | Phase 2 | Completed | Harlan M Krumholz | 100 | 2023-04-14 | 2024-12-02 |
| A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19 Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19) | Phase 2 | Withdrawn | Pfizer | 2022-12-13 | 2023-03-01 | |
| A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women nirmatrelvir, ritonavir - Healthy Participants | Phase 1 | Completed | Pfizer | 8 | 2022-12-12 | 2026-05-01 |
| Paxlovid for Treatment of Long Covid Nirmatrelvir, Placebo, Ritonavir - Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID | Phase 2 | Completed | Stanford University | 168 | 2022-11-08 | 2025-09-04 |
| A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir nirmatrelvir, ritonavir, placebo for nirmatrelvir - COVID-19 | Phase 2 | Completed | Pfizer | 436 | 2022-10-19 | 2024-10-08 |
| A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease PF-07321332 (nirmatrelvir)/ritonavir - COVID-19 | Phase 1 | Terminated | Pfizer | 15 | 2022-09-07 | 2024-09-23 |
| Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium) Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose), Nirmatrelvir 150 mg + Ritonavir 100 mg (test), Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose) - Healthy | Phase 1 | Completed | Genuine Research Center, Egypt | 28 | 2022-08-21 | 2023-01-18 |
| A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir - COVID-19 | Phase 2 | Completed | Pfizer | 158 | 2022-08-03 | 2024-09-23 |
| A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19 nirmatrelvir, ritonavir - COVID-19 | Phase 1 | Terminated | Pfizer | 25 | 2022-06-22 | 2026-08-17 |
| Saliva PCR in Pregnant Women with COVID-19 Nirmatrelvir/Ritonavir (Paxlovid) - Coronavirus Disease 2019 (COVID-19) Pneumonia | Completed | National Cheng-Kung University Hospital | 37 | 2022-06-01 | 2024-12-16 | |
| The Safety of Paxlovid in Hemodialysis Patients With Covid-19 Nirmatrelvir and ritonavir stage 1, Nirmatrelvir and ritonavir stage 2 - Safety Issues | Phase 4 | Completed | RenJi Hospital | 18 | 2022-05-06 | 2022-06-14 |
| EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease nirmatrelvir, ritonavir - COVID-19 | Phase 3 | Recruiting | Pfizer | 160 | 2022-03-07 | 2025-07-17 |
| Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation PF-07321332/ritonavir, PF-07321332 - Bioavailability | Phase 1 | Completed | Pfizer | 12 | 2022-03-03 | 2025-06-11 |
| Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™) - COVID-19 | Phase 2 | Recruiting | University of Oxford | 3800 | 2021-09-30 | 2026-02-19 |
| PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran - Healthy Participants | Phase 1 | Completed | Pfizer | 24 | 2021-09-21 | 2024-03-29 |
| Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants Midazolam, PF-07321332/ritonavir + Midazolam, Ritonavir + Midazolam - Healthy Participants | Phase 1 | Completed | Pfizer | 12 | 2021-09-17 | 2023-10-04 |
| A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection PF-07321332, Placebo for PF-07321332, Placebo for Ritonavir - COVID-19 | Phase 2 / Phase 3 | Completed | Pfizer | 2954 | 2021-09-09 | 2023-05-06 |
| Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332 PF-07321332, Ritonavir - Hepatic Impairment | Phase 1 | Completed | Pfizer | 17 | 2021-08-31 | 2023-09-06 |
Showing 20 of 24. Sign in to see all of them.
COVID-19 (20) · Pneumonia (3) · Lung Diseases (2) · Post-Acute COVID-19 Syndrome (2) · Renal Insufficiency (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Breast Feeding (1) · COVID-19 rebound (1) · Community-Acquired Pneumonia (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Infections (1) · Influenza, Human (1) · Kidney Diseases (1)
Pfizer (16) · Genuine Research Center, Egypt (1) · Harlan M Krumholz (1) · National Cheng-Kung University Hospital (1) · National Taiwan University Hospital (1) · RenJi Hospital (1) · Stanford University (1) · UMC Utrecht (1) · University of Oxford (1)
United States (16) · Bulgaria (6) · Brazil (5) · Hungary (5) · Japan (5) · Mexico (5) · Spain (5) · Colombia (4) · Czechia (4) · South Africa (4) · Thailand (4) · Argentina (3) · Belgium (3) · Canada (3) · Malaysia (3)
Ahmed Elshafeey, Ph.D. Pharma (1) · Akiko Iwasaki, PhD (1) · Colin McArthur, Dr (1) · Derek Angus, Prof (1) · Harlan M Krumholz, MD, SM (1) · John Marshall, Prof (1) · Lennie Derde, MD (1) · Leyi Gu (1) · Linda Geng, MD, PhD (1) · Marc Bonten, Prof (1) · Steve Webb, Prof (1) · Upinder Singh, MD (1)
PMID 40592258, PMID 37231296, PMID 37354048, PMID 32267771, PMID 32876697, PMID 33394942, PMID 33509275, PMID 33631065, PMID 34251506, PMID 34351721, PMID 34351722, PMID 34473343, PMID 34606578, PMID 35172054, PMID 35315874, PMID 35712797, PMID 36803992, PMID 36942550, PMID 36967714, PMID 37039790, PMID 37470445, PMID 37489818, PMID 37778363, PMID 37877585, PMID 37888913, PMID 38225598, PMID 38598573, PMID 38677300, PMID 38848477, PMID 39018532, PMID 39523543, PMID 39896880, PMID 40188838, PMID 40261382, PMID 40360262, PMID 40675169, PMID 40788441, PMID 40809391, PMID 40810942, PMID 41027009, PMID 41082886, PMID 41085942, PMID 41321979, PMID 41823072, PMID 41857593, PMID 42012328, PMID 42823695
2023 (3), 2015 (1)